In order to address the urgent unmet medical need in malignant mesothelioma, a consortium of leading European university hospitals is preparing a clinical study called DENIM (H2020MM04). The objective of the DENIM study is to demonstrate the efficacy and safety of dendritic cell-based immunotherapy in a randomized phase II/III clinical study.
DENIM clinical study
DENIM is an abbreviation of DENdritic cell Immunotherapy for Mesothelioma.
